Biotech Company XO1 Raises $11M from Index Ventures
June 19, 2013
XO1, a developer of anticoagulant drugs, has raised an $11 million round of Series A funding from Index Ventures. The company will use the proceeds to develop an antibody invented at the University of Cambridge, called ichorcumab, which has the potential to prevent heart attack and stroke without causing bleeding. XO1 is a virtual company with no offices or laboratory space, operating by outsourcing contract research and development specialists in Europe and the U.S.